Click here to learn more

Scroll over the words in bold for brief definitions.

Complete and Long-Lasting Response

ILARIS® Delivered Much-Needed Relief in CAPS (Cryopyrin-Associated Periodic Syndrome)

In a clinical study of 35 patients, ILARIS® (canakinumab) provided complete and long-lasting response from a rare, genetic condition called CAPS. (Learn more about CAPS in the section Facts About CAPS .)

97% of Patients Had Complete Response Within the First Treatment Period (8 Weeks)

  • The majority of patients (71%) experienced a complete response in just 7 days
    • Complete response was measured by lab results and by the doctor's evaluation of the patient's skin disease and symptoms being minimal or better, including symptoms such as:
      • Rash
      • Fatigue
      • Muscle pain
      • Headache or migraine
      • Sore or red eyes
      • Joint pain

The Majority of Patients Had Long-Lasting Response

  • In a clinical study, no ILARIS® patients experienced a flare of their symptoms over 8 months (just 4 treatments)
    • A flare was measured by lab results and by the doctor's evaluation of the patient's symptoms being mild or worse, or an evaluation of both the patient's symptoms and skin disease being minimal or worse

ILARIS® Patient Support Program

The ILARIS® Patient Support Program provides patients with information and tools to assist in managing their treatment with ILARIS® and helps to identify resources that can assist with payment for their medication.
Learn More

Register for ILARIS Updates

Sign up here for ILARIS® Direct and stay current with news about ILARIS®.
Register


isi-Consumer www.fda.gov/medwatch full prescribing information